Soluble CD30 and Cd27 levels in patients undergoing HLA antibody-incompatible renal transplantation

Transplant Immunology

Volumn 23, Issue 4, 2010, Pages 161-165

  Hamer, Rizwan ^a,c   Roche, Laura ^b   Smillie, David ^b   Harmer, Andrea ^b   Mitchell, Daniel ^c   Molostvov, Guerman ^c   Lam, For T ^a   Kashi, Habib ^a   Tan, Lam Chin ^a   Imray, Chris ^a   Fletcher, Simon ^a   Briggs, David ^b   Lowe, David ^b,c   Zehnder, Daniel ^a,c   Higgins, Rob ^a  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^b NHS BLOOD AND TRANSPLANT   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

CD27; CD30; HLA antibody incompatible transplantation

Indexed keywords

BASILIXIMAB; CD27 ANTIGEN; CD30 ANTIGEN; CREATININE; HLA ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ANTIBODY SPECIFICITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT RECIPIENT; HIGH RISK PATIENT; HLA MATCHING; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; ANTIGENS, CD27; ANTIGENS, CD30; BIOLOGICAL MARKERS; CREATININE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HLA ANTIGENS; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS;

EID: 77956064179     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2010.06.004     Document Type: Article

References (31)

1. Hamer R., El Nahas A. The burden of chronic kidney disease. BMJ 2006, 332:563-564.
2. Norman D. The kidney transplant wait-list: allocation of patients to a limited supply of organs. Semin Dial 2005, 18:456-459.
3. Higgins R., Hathaway M., Lowe D., Zehnder D., Krishnan N., Hamer R., et al. New choices for patients needing kidney transplantation across antibody barriers. J Ren Care 2008, 34:85-93.
4. Stegall M., Gloor J., Winters J., Moore S., Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006, 6:346-351.
5. Gwinner W. Renal transplant rejection markers. World J Urol 2007, 25:445-455.
6. Pelzl S., Opelz G., Wiesel M., Schnülle P., Schönemann C., Döhler B., et al. Soluble CD30 as a predictor of kidney graft outcome. Transplantation 2002, 73:3-6.
7. Süsal C., Pelzl S., Döhler B., Opelz G. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 2002, 13:1650-1656.
8. Schwab U., Stein H., Gerdes J., Lemke H., Kirchner H., Schaadt M., et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982, 299:65-67.
9. Tarkowski M. Expression and a role of CD30 in regulation of T-cell activity. Curr Opin Hematol 2003, 10:267-271.
10. Pelzl S., Opelz G., Daniel V., Wiesel M., Süsal C. Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation 2003, 75:421-423.
11. Slavcev A., Lácha J., Honsová E., Sajdlová H., Lodererová A., Vitko S., et al. Soluble CD30 and HLA antibodies as potential risk factors for kidney transplant rejection. Transpl Immunol 2005, 14:117-121.
12. Weimer R., Süsal C., Yildiz S., Streller S., Pelzl S., Staak A., et al. sCD30 and neopterin as risk factors of chronic renal transplant rejection: impact of cyclosporine A, tacrolimus, and mycophenolate mofetil. Transplant Proc 2005, 37:1776-1778.
13. Langan L., Park L., Hughes T., Irish A., Luxton G., Witt C., et al. Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival. Am J Transplant 2007, 7:847-856.
14. Rajakariar R., Jivanji N., Varagunam M., Rafiq M., Gupta A., Sheaff M., et al. High pre-transplant soluble CD30 levels are predictive of the grade of rejection. Am J Transplant 2005, 5:1922-1925.
15. Vaidya S., Partlow D., Barnes T., Gugliuzza K. Pretransplant soluble CD30 is a better predictor of posttransplant development of donor-specific antibodies and acute vascular rejection than panel reactive antibodies. Transplantation 2006, 82:1606-1609.
16. Slavcev A., Honsova E., Lodererova A., Pavlova Y., Sajdlova H., Vitko S., et al. Soluble CD30 in patients with antibody-mediated rejection of the kidney allograft. Transpl Immunol 2007, 18:22-27.
17. Maurer D., Fischer G., Fae I., Majdic O., Stuhlmeier K., Von Jeney N., et al. IgM and IgG but not cytokine secretion is restricted to the CD27+ B lymphocyte subset. J Immunol 1992, 148:3700-3705.
18. Agematsu K., Nagumo H., Yang F., Nakazawa T., Fukushima K., Ito S., et al. B cell subpopulations separated by CD27 and crucial collaboration of CD27+ B cells and helper T cells in immunoglobulin production. Eur J Immunol 1997, 27:2073-2079.
19. Klein U., Rajewsky K., Küppers R. Human immunoglobulin (Ig)M+IgD+peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med 1998, 188:1679-1689.
20. Agematsu K., Hokibara S., Nagumo H., Shinozaki K., Yamada S., Komiyama A. Plasma cell generation from B-lymphocytes via CD27/CD70 interaction. Leuk Lymphoma 1999, 35:219-225.
21. Font J., Pallares L., Martorell J., Martinez E., Gaya A., Vives J., et al. Elevated soluble CD27 levels in serum of patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1996, 81:239-243.
22. Tak P., Hintzen R., Teunissen J., Smeets T., Daha M., van Lier R., et al. Expression of the activation antigen CD27 in rheumatoid arthritis. Clin Immunol Immunopathol 1996, 80:129-138.
23. van Oers M., Pals S., Evers L., van der Schoot C., Koopman G., Bonfrer J., et al. Expression and release of CD27 in human B-cell malignancies. Blood 1993, 82:3430-3436.
24. Widney D., Gundapp G., Said J., van der Meijden M., Bonavida B., Demidem A., et al. Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. Clin Immunol 1999, 93:114-123.
25. Nakatsuji T. High levels of serum soluble CD27 correlated with renal dysfunction. Clin Exp Med 2003, 2:192-196.
26. Montgomery R., Zachary A. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr Transplant 2004, 8:535-542.
27. Racusen L., Colvin R., Solez K., Mihatsch M., Halloran P., Campbell P., et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003, 3:708-714.
28. Chamuleau M., ten Berge I., Schellekens P., Wilmink J., Hintzen R., van Lier R. Serum levels of soluble CD27 in renal transplant recipients. Transplantation 1992, 54:932-936.
29. Nakao K., Nagake Y., Okamoto A., Ichikawa H., Yamamura M., Makino H. Serum levels of soluble CD26 and CD30 in patients on hemodialysis. Nephron 2002, 91:215-221.
30. Girndt M., Sester M., Sester U., Kaul H., Köhler H. Molecular aspects of T- and B-cell function in uremia. Kidney Int Suppl 2001, 78:S206-S211.
31. Weimer R., Süsal C., Yildiz S., Staak A., Pelzl S., Renner F., et al. Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens. Am J Transplant 2006, 6:1865-1874.